Tom T. Shimabukuro

11.5k citations

92 papers · 4.8k indexed · 7 hit papers · h-index 37

Health top 0.2%
- Vaccine Coverage and Hesitancy 49
Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research 41
Toxicology top 1%
- Pharmacovigilance and Adverse Drug Reactions 15
Modeling and Simulation top 1%
Obstetrics and Gynecology top 2%
Epidemiology
- Influenza Virus Research Studies 24
Cardiology and Cardiovascular Medicine
- Viral Infections and Immunology Research 13
Surgery
- Heparin-Induced Thrombocytopenia and Thrombosis 12
Emergency Medicine
- Intramuscular injections and effects 12
Pharmacology
- Drug-Induced Adverse Reactions 8

Co-authors: John R. Su Frank DeStefano Narayan Nair David K. Shay Julianne Gee Paige Marquez Tanya R. Myers David Martin
Cited by: Health Infectious Diseases Toxicology
Journals: JAMA (3 papers)PEDIATRICS (3 papers)Clinical Infectious Diseases (2 papers)
Partner nations: United States Uganda Switzerland

In The Last Decade

Tom T. Shimabukuro

91 papers receiving 4.6k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 The Lancet Infectious Diseases
2021 JAMA
2021 MMWR Morbidity and Mortality Weekly Report
2021 JAMA
2021 MMWR Morbidity and Mortality Weekly Report
2021 JAMA
2015 Vaccine

Peers

Countries citing papers authored by Tom T. Shimabukuro

Since Specialization

Citations

This map shows the geographic impact of Tom T. Shimabukuro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom T. Shimabukuro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom T. Shimabukuro more than expected).

Fields of papers citing papers by Tom T. Shimabukuro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom T. Shimabukuro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom T. Shimabukuro. The network helps show where Tom T. Shimabukuro may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tom T. Shimabukuro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom T. Shimabukuro Line = papers co-authored together Tom T. Shimabukuro links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink American Journal of Otolaryngology ·W. Katherine Yih,Jonathan Duffy,John R. Su,Samaneh Bazel,Bruce Fireman,Laura P. Hurley,Judith C. Maro,Paige Marquez,Pedro L. Moro,Narayan Nair,Jennifer C. Nelson,Ning Smith,Maria E. Sundaram,Gabriela Vasquez-Benitez,Eric Weintraub,Stanley Xu,Tom T. Shimabukuro	2024	1
2	Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic Vaccine ·Dana Meaney‐Delman,Sarah Carroll,Kara N.D. Polen,Tara C. Jatlaoui,Sarah Meyer,Sara E. Oliver,Julianne Gee,Tom T. Shimabukuro,Hilda Razzaghi,Laura E. Riley,Romeo R. Galang,Van T. Tong,Suzanne M. Gilboa,Sascha Ellington,Amanda Cohn	2024	3
3	A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States Vaccine ·Megan Wallace,Hannah G. Rosenblum,Danielle Moulia,Karen R. Broder,Tom T. Shimabukuro,Christopher A. Taylor,Fiona P. Havers,Sarah Meyer,Kathleen Dooling,Sara E. Oliver,Stephen C. Hadler,Julia W. Gargano	2023	11
4	Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023 MMWR Morbidity and Mortality Weekly Report ·Anne M. Hause,Paige Marquez,Bicheng Zhang,John R. Su,Tanya R. Myers,Julianne Gee,S. Panchanathan,Deborah Thompson,Tom T. Shimabukuro,David K. Shay	2023	23
5	Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023 MMWR Morbidity and Mortality Weekly Report ·Brittney Romanson,Pedro L. Moro,John R. Su,Paige Marquez,Narayan Nair,Brendan Day,Allison DeSantis,Tom T. Shimabukuro	2023	2
6	Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States JAMA Network Open ·Winston E. Abara,Julianne Gee,Paige Marquez,Jared Woo,Tanya R. Myers,Allison DeSantis,Jane Baumblatt,Emily Jane Woo,Deborah Thompson,Narayan Nair,John R. Su,Tom T. Shimabukuro,David K. Shay	2023	41
7	Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults Vaccine ·Lindsay K. Tompkins,James Baggs,Tanya R. Myers,Julianne Gee,Paige Marquez,Sharon B. Kennedy,D. J. Peake,Dhruv Dua,Anne M. Hause,Penelope Strid,Winston E. Abara,Rebecca Rossetti,Tom T. Shimabukuro,David K. Shay	2022	2
8	Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring The Journal of Infectious Diseases ·Winston E. Abara,Julianne Gee,Mark Delorey,Tun Ye,Yi Mu,David K. Shay,Tom T. Shimabukuro	2021	7
9	Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system Vaccine ·Johanna Chapin-Bardales,Tanya R. Myers,Julianne Gee,David K. Shay,Paige Marquez,James Baggs,Bicheng Zhang,Charles Licata,Tom T. Shimabukuro	2021	10
10	Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020 American Journal of Transplantation ·Tom T. Shimabukuro	2021	52
11	Vaccine Adverse Event Reporting System Journal of Vaccines & Vaccination ·Tom T. Shimabukuro	2020	0
12	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15 Vaccine ·James G. Donahue,Burney A. Kieke,Jennifer P. King,Maria Mascola,Tom T. Shimabukuro,Frank DeStefano,Kayla E. Hanson,David L. McClure,Oluwatosin Olaiya,Jason M. Glanz,Rulin C. Hechter,Stephanie A. Irving,Lisa A. Jackson,Nicola P. Klein,Allison L. Naleway,Eric Weintraub,Edward A. Belongia	2019	37
13	Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting Biologicals ·Kathryn M. Edwards,Germaine Hanquet,Steve Black,Emmanuel Mignot,Christopher Jankosky,Tom T. Shimabukuro,Elizabeth Miller,Hanna Nohynek,Pieter Neels	2019	11
14	Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015 Vaccine ·Jorge E. Araña,Theresa Harrington,Maria Cano,Paige Lewis,Adamma Mba‐Jonas,Rongxia Li,Brock Stewart,Lauri E. Markowitz,Tom T. Shimabukuro	2018	51
15	Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12 The Lancet Infectious Diseases ·Shahed Iqbal,Jing Shi,Katherine Seib,Paige Lewis,Pedro L. Moro,Emily Jane Woo,Tom T. Shimabukuro,Walter A. Orenstein	2015	9
16	Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997–2013 Clinical Infectious Diseases ·Pedro L. Moro,Jorge E. Araña,Maria Cano,Paige Lewis,Tom T. Shimabukuro	2015	27
17	Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005–June 2013 Vaccine ·Penina Haber,Pedro L. Moro,Michael M. McNeil,Paige Lewis,Emily Jane Woo,Hayley Hughes,Tom T. Shimabukuro	2014	16
18	Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students—Iowa, 2006 Vaccine ·Mona Marin,Patricia Quinlisk,Tom T. Shimabukuro,Charu Sawhney,Cedric Brown,Charles W. LeBaron	2008	117
19	Potential for Improving Age-Appropriate Vaccination Coverage by Maximizing the 18-Month Well-Child Visit Journal of Public Health Management and Practice ·Tom T. Shimabukuro,Elizabeth T. Luman,Carla A. Winston,Richard A. Schieber	2007	2
20	Medical Expenditures for Children with an Autism Spectrum Disorder in a Privately Insured Population Journal of Autism and Developmental Disorders ·Tom T. Shimabukuro,Scott D. Grosse,Catherine E. Rice	2007	127

About Tom T. Shimabukuro

Tom T. Shimabukuro is a scholar working on Health, Toxicology and Infectious Diseases, having authored 92 papers that have together received 4.8k indexed citations. Recurring topics across this work include Vaccine Coverage and Hesitancy (49 papers), SARS-CoV-2 and COVID-19 Research (41 papers), Influenza Virus Research Studies (24 papers), Pharmacovigilance and Adverse Drug Reactions (15 papers), Viral Infections and Immunology Research (13 papers), Heparin-Induced Thrombocytopenia and Thrombosis (12 papers), Intramuscular injections and effects (12 papers) and Drug-Induced Adverse Reactions (8 papers). The work is most often cited by research in Health (1.6k citations), Infectious Diseases (2.5k citations) and Toxicology (177 citations). Tom T. Shimabukuro has collaborated with scholars based in United States, Uganda and Switzerland. Frequent co-authors include John R. Su, Frank DeStefano, Narayan Nair, David K. Shay, Julianne Gee, Paige Marquez, Tanya R. Myers, David Martin, Michael Nguyen and Matt Cole. Their work appears in journals such as JAMA, PEDIATRICS and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact